CLIMB BIO, INC. Unrealized Gain (Loss) on Investments
CLIMB BIO, INC. (CLYM) reported Unrealized Gain (Loss) on Investments of $263.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2025-05-14
- CLIMB BIO, INC. unrealized gain (loss) on investments for the quarter ending 2025-03-31 was $263.00K, a 13050.00% increase year-over-year.
- CLIMB BIO, INC. unrealized gain (loss) on investments for the quarter ending 2024-12-31 was -$178.00K, a 2077.78% decline year-over-year.
- CLIMB BIO, INC. unrealized gain (loss) on investments for the quarter ending 2024-09-30 was $201.00K, a 737.50% increase year-over-year.
- CLIMB BIO, INC. unrealized gain (loss) on investments for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- CLIMB BIO, INC. unrealized gain (loss) on investments for fiscal 2024 was $25.00K, a 92.98% decline from fiscal 2023.
- CLIMB BIO, INC. unrealized gain (loss) on investments for fiscal 2023 was $356.00K.
- CLIMB BIO, INC. unrealized gain (loss) on investments for fiscal 2022 was -$235.00K.
- CLIMB BIO, INC. unrealized gain (loss) on investments for fiscal 2021 was -$123.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 3 month as first filed | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|---|
| 2025-03-31 | $263.00K 10-Q · filed 2025-05-14 | $85.00K derived: sum of 2 quarters · filed 2025-05-14 | $286.00K derived: sum of 3 quarters · filed 2025-05-14 | $286.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $23.00K derived: sum of 2 quarters · filed 2025-03-25 | $23.00K derived: sum of 3 quarters · filed 2025-03-25 | $25.00K 10-K · filed 2025-03-25 | |
| 2024-09-30 | $201.00K 10-Q · filed 2024-11-12 | $201.00K derived: sum of 2 quarters · filed 2024-11-12 | $203.00K 10-Q · filed 2024-11-12 | $212.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $2.00K 10-Q · filed 2024-08-14 | $11.00K derived: sum of 3 quarters · filed 2025-05-14 | $35.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-14 | $11.00K derived: sum of 2 quarters · filed 2025-05-14 | $35.00K derived: sum of 3 quarters · filed 2025-05-14 | $95.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $33.00K derived: sum of 2 quarters · filed 2025-03-25 | $93.00K derived: sum of 3 quarters · filed 2025-03-25 | $356.00K 10-K · filed 2025-03-25 | |
| 2023-09-30 | $24.00K 10-Q · filed 2024-11-12 | $84.00K derived: sum of 2 quarters · filed 2024-11-12 | $347.00K 10-Q · filed 2024-11-12 | $570.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $60.00K 10-Q · filed 2024-08-14 | $323.00K 10-Q · filed 2024-08-14 | $546.00K derived: sum of 3 quarters · filed 2024-08-14 | $569.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $263.00K 10-Q · filed 2024-05-15 | $486.00K derived: sum of 2 quarters · filed 2024-05-15 | $509.00K derived: sum of 3 quarters · filed 2024-05-15 | $426.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $246.00K derived: sum of 2 quarters · filed 2024-03-28 | $163.00K derived: sum of 3 quarters · filed 2024-03-28 | -$235.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $23.00K 10-Q · filed 2023-11-14 | -$60.00K derived: sum of 2 quarters · filed 2023-11-14 | -$458.00K 10-Q · filed 2023-11-14 | -$563.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$83.00K 10-Q · filed 2023-08-10 | -$481.00K 10-Q · filed 2023-08-10 | -$586.00K derived: sum of 3 quarters · filed 2023-08-10 | -$568.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$398.00K 10-Q · filed 2023-05-11 | -$503.00K derived: sum of 2 quarters · filed 2023-05-11 | -$485.00K derived: sum of 3 quarters · filed 2023-05-11 | -$485.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$87.00K derived: sum of 2 quarters · filed 2023-03-06 | -$87.00K derived: sum of 3 quarters · filed 2023-03-06 | -$123.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $18.00K 10-Q · filed 2022-11-14 | -$18.00K 10-Q · filed 2021-11-08 | $18.00K derived: sum of 2 quarters · filed 2022-11-14 | -$18.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |